Collegium Pharmaceutical, Inc., a Canton, MA-based specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, raised $50m in funding.
The round was led by TPG Biotech, with participation from RA Capital Management, Adage Capital Management, Rock Springs Capital, EcoR1 Capital, Eventide Asset Management and Aperture Venture Partners and existing investors Longitude Capital, Skyline Ventures, Frazier Healthcare and Boston Millennia Partners. In conjunction with the financing, Eran Nadav, Ph.D., Partner and Managing Director of TPG Biotech, will join Collegium’s Board of Directors.
The company plans to use the funds to advance its lead abuse-deterrent product candidate, Xtampza ER (oxycodone extended-release capsules), through potential FDA approval and commercial launch as well as to grow operations and other pipeline development programs.
The FDA accepted for filing Collegium’s New Drug Application (NDA) for Xtampza ER in February 2015.
Led by Michael Heffernan, CEO, Collegium Pharmaceutical focuses on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain.